98%
921
2 minutes
20
Purpose: To assess the relationship between perirectal hydrogel spacer placement and the clinical outcomes in men undergoing radiotherapy (RT) for prostate cancer.
Materials And Methods: An extensive literature review was conducted using the PubMed/Medline, Embase, Cochrane Library, and Web of Science databases, encompassing studies published through June 2024. Group comparisons were performed using the weighted mean difference for continuous variables and the risk ratio for dichotomous measures. The primary endpoint was to compare rectal radiation doses with or without a perirectal spacer. Secondary outcomes included gastrointestinal (GI) and genitourinary (GU) toxicities (acute/late and any/grade ≥2, with subgroup analyses for hypofractionated RT.
Results: We reviewed 35 studies comprising 4,664 males. Rectal spacers effectively reduced the mean and maximum rectal radiation exposure, with reductions of 51.8% in V50 (mL) and 56.8% in V70 (mL). Furthermore, the percentage-based analysis showed reductions of 54.5% in V50 (%) and 62.2% in V70 (%). Acute GU toxicities (any grade and grade ≥2) showed no significant difference between the spacer and no-spacer groups, with no subgroup differences by fractionation. Late GU toxicities (any grade) were lower in the spacer group, while grade ≥2 toxicities showed no difference. Acute GI toxicities (any grade) were significantly reduced with spacers, particularly in hypofractionated RT, while grade ≥2 toxicities showed no difference. Late GI toxicities (any grade) were lower in the spacer group, with a stronger protective effect in hypofractionated RT. No significant difference was observed in grade ≥2 late GI toxicities.
Conclusions: Hydrogel spacers significantly reduced rectal radiation exposure and overall GI toxicity. However, their limited impact on severe toxicity highlights the need for further research on high-risk treatments and advanced RT techniques.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5534/wjmh.250043 | DOI Listing |
Oncologist
September 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.
View Article and Find Full Text PDFBlood Neoplasia
November 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123 monocytes and plasmacytoid dendritic cells (pDCs). pDC bone marrow clusters in CMML have been associated with higher rates of acute myeloid leukemia transformation. We evaluated tagraxofusp, a CD123-targeted therapy, in a phase 1/2 trial for patients with CMML.
View Article and Find Full Text PDFRep Pract Oncol Radiother
August 2025
Hospital General de Mexico "Dr Eduardo Liceaga", Mexico City, Mexico.
Background: Paragangliomas are highly vascularized tumours that have benign histology, with malignant dissemination being infrequent (< 5%). Surgery is the only option offering complete resection; however, there is significant morbidity. Treatment with radiotherapy (RT) offers good results in controlling the disease.
View Article and Find Full Text PDFFront Oncol
August 2025
Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.
View Article and Find Full Text PDFIntroduction: The combination of 3D radiation therapy (3D-RT) with cisplatin has been the conventional treatment for squamous cell carcinoma of the head and neck for decades.
Aims: To assess the impact of 3D radiotherapy with cisplatin on the Eastern Cooperative Oncology Group (ECOG) performance status and quality of life in terms of acute side effects among head and neck cancer patients.
Methodology: After obtaining the hospital's ethical approval, 106 head and neck cancer patients were enrolled at the Institute of Nuclear Medicine and Oncology, Lahore, Pakistan.